1-3 of 3
Ashish V. Kalra
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion

Ashish V. Kalra, Jaeyeon Kim, Stephan G. Klinz, Nancy Paz, Jason Cain, Daryl C. Drummond, Ulrik B. Nielsen, Jonathan B. Fitzgerald
Journal: Cancer Research
Series: Author Choice
Cancer Res (2014) 74 (23): 7003–7013.
https://doi.org/10.1158/0008-5472.CAN-14-0572
Published: 30 November 2014
View article titled, Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
Open the PDF for Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion in another window
Includes: Supplementary data
Journal Articles

Abstract 2065: Magnetic resonance imaging with an iron oxide nanoparticle demonstrates the preclinical feasibility of predicting intratumoral uptake and activity of MM-398, a nanoliposomal irinotecan (nal-IRI)

Ashish V. Kalra, Joseph Spernyak, Jaeyeon Kim, Arnold Sengooba, Stephan Klinz, Nancy Paz, Jason Cain, Walid Kamoun, Ninfa Straubinger, Yang Qu, Sheryl Trueman, Eliel Bayever, Ulrik Nielsen, Daryl Drummond, Jonathan Fitzgerald, Robert Straubinger
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2065.
https://doi.org/10.1158/1538-7445.AM2014-2065
Published: 01 October 2014
View article titled, Abstract 2065: Magnetic resonance imaging with an iron oxide nanoparticle demonstrates the preclinical feasibility of predicting intratumoral uptake and activity of MM-398, a nanoliposomal irinotecan (nal-IRI)
Journal Articles

Development of drug-loaded PCLs against human pancreatic cancer: Implications for site-specific tumor vascular targeting

Ashish V. Kalra, Robert B. Campbell
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 723.
Published: 15 April 2006
View article titled, Development of drug-loaded PCLs against human pancreatic cancer: Implications for site-specific tumor vascular targeting